[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584152":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":28,"locations":33,"responsibleParty":51,"collaborators":53,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with STEMI",null,"First-STEMI patients treated with primary PCI (symptom-to-PCI ≤12 h, TIMI 3) were enrolled within 24 h post-PCI.",[13],"Other: Diagnostic Test: echocardiography and blood collection",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Diagnostic Test: echocardiography and blood collection","Blood samples were collected from all patients at enrollment (within 24 hours after primary PCI), at days 3-5, and at months 1, 3, and 6 after enrollment. Echocardiography was performed at enrollment (baseline, within 24-48 hours after admission), and at months 1, 3, and 6 after enrollment.",[9],[20,24],{"name":21,"affiliation":22,"role":23},"Xu Wang, Dr.","Beijing Anzhen hospital, Capital Mediacl University.","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":26,"role":27},"Tanxi Cai, Dr.","Institute of Biophysics, Chinese Academy of Sciences","STUDY_DIRECTOR",[29],{"name":21,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+8617810688257","huaianwangxu@126.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Beijing Anzhen Hospital, Capital Medical University.","RECRUITING","Beijing","Beijing Municipality","100029","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49,50],{"name":21,"role":30,"phone":31,"phoneExt":10,"email":32},{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[54,56],{"name":55,"class":6},"Beijing Jishuitan Hospital",{"name":26,"class":57},"UNKNOWN","100584152","prediction-of-lvar-and-mace-in-stemi-though-plasma-multiomics-analysis-100584152",false,"NCT06885619","Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis","Prediction of Left Ventricular Adverse Remodeling and Major Adverse Cardiovascular Events in Patients With Acute ST-segment Elevation Myocardial Infarction Though Plasma Multiomics Analysis","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years.\n2. Definite diagnosis of STEMI according to ESC\u002FACC guidelines:\n\n   * Chest pain lasting \\>30 minutes, and\n   * ST-segment elevation in at least two contiguous leads: ≥0.2 mV in leads V2-V3 (≥0.2 mV for men, ≥0.15 mV for women) or ≥0.1 mV in other leads, or new-onset left bundle branch block.\n3. Reperfusion therapy: Symptom onset to first medical contact ≤12 hours, and successful primary PCI (culprit vessel opened, post-procedure TIMI flow grade 3).\n4. First STEMI (no prior history of myocardial infarction).\n5. Left ventricular ejection fraction (by echocardiography within 24-48 hours after admission) ≥35%.\n6. Informed consent: Signed informed consent obtained, with willingness to undergo serial blood sampling and echocardiographic follow-up.\n\nExclusion Criteria:\n\n1. Non-atherosclerotic MI: coronary embolism, spasm, aortic dissection, myocarditis, Takotsubo.\n2. Severe comorbidities:\n\n   * Prior HF (NYHA ≥II);\n   * Severe CKD (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² or dialysis);\n   * Severe liver disease (Child-Pugh B\u002FC);\n   * Active malignancy (life expectancy \\\u003C1 year);\n   * Severe hematologic disorders (thrombocytopenia, coagulopathy, active bleeding).\n3. Fibrinolysis-followed-by-PCI.\n4. Primary PCI complications:\n\n   * No-reflow\u002Fslow-flow (final TIMI \\\u003C2);\n   * Cardiogenic shock or mechanical complication within 7 days;\n   * In-hospital repeat revascularization.\n5. Inability to complete 6-month follow-up.\n6. Factors affecting blood sampling\u002Fexosome\u002Fimmune\u002Fproteome assays:\n\n   * Blood transfusion within 1 month;\n   * Known hemolytic disorder;\n   * Inadequate venous access.\n7. Pregnancy or lactation.","ALL","18 Years","80 Years",{"count":69,"type":70},1000,"ESTIMATED","OBSERVATIONAL","To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.",[74,75,76,77,78],"Left Ventricular Remodeling","Plasma Multi-Omics","Acute ST-segment Elevation Myocardial Infarction","Immunomics","Major Adverse Cardiovascular Events","2026-05-07",{"date":81,"type":82},"2026-05-12","ACTUAL",{"date":84,"type":82},"2025-05-01",{"date":86,"type":70},"2027-12-31",{"name":5,"class":6},1]